Research programme: cancer therapeutics - Mateon Therapeutics

Drug Profile

Research programme: cancer therapeutics - Mateon Therapeutics

Alternative Names: KGP 207; KGP-156; KGP-18; KGP-94

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baylor University; OXiGENE
  • Developer Mateon Therapeutics
  • Class Benzophenones; Small molecules; Thiosemicarbazones
  • Mechanism of Action Cathepsin K inhibitors; Cathepsin L inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Oct 2016 Mateon Therapeutics has patent protection for cathepsin inhibition in USA
  • 17 Jun 2016 OXiGENE is now called Mateon Therapeutics
  • 01 Apr 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top